Trial Purpose

The goal of this study is to evaluate the efficacy and safety of pembrolizumab combined with carboplatin and paclitaxel as first line treatment in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.

View full trial information on Clinicaltrials.gov

CLINICALTRIALS.GOV IDENTIFIER:

NCT04489888

When speaking to your doctor, please have the trial identifier number available.

About The Trial

Trial Phase Icon

Phase 4

Thousands of people usually participate in ongoing trials. Phase 4 clinical trials are conducted after the medicine or vaccine has been approved by the appropriate government and regulatory agencies and is being marketed.

Trial start Icon

Dates

  • Actual study start date October 27, 2020
  • Estimated primary completion date February 20, 2023
  • Estimated study completion date July 25, 2024

Eligibility

Conditions Icon

Conditions

Squamous Cell Carcinoma Of Head And Neck

Age Range Icon

Age Range

18 - No Age Maximum

Sex Icon

Sex

All

Trial locations

What Can You Do Next?

If you think this trial might be a fit and are interested in participating, take the next step to see if you are eligible.

Discuss Icon

Discuss With Your Doctor

Print this page or email it to your doctor to discuss at your next visit.

CLINICALTRIALS.GOV IDENTIFIER:

NCT04489888

When speaking to your doctor, please have the trial identifier number available.

Participating in a clinical trial is an important decision.

Anyone participating in a trial should know as much as possible about what is being studied, what risks are involved and what potential benefits may be gained before deciding to enroll. If you are interested in participating in a clinical trial, please talk to your doctor first.